Skip to main content

Another Company, Another Childhood

Premium

Frank Lee swears it’s not a midlife crisis. Lee, 49, left his CTO post at Millennium Pharmaceuticals to become president and CEO of EngeneOS, a startup with fewer than 10 employees incubated by NewcoGen. “I was interested in going back to an earlier stage company,” says Lee, who remembers well Millennium’s nascent phase. Another attraction was the added responsibility: “I wanted to move from the pure science and technology role.”

The switch to CEO and president should accomplish that. EngeneOS hopes to develop a business around disciplines as varied as biology, genomics, physics, engineering, and electronics. The goal is to engineer electronic devices using peptides or nucleic acids as scaffolds. Potential applications exist in pharmaceuticals, diagnostics, and chemical synthesis.

Lee expects the company to grow through internal expansion of its science and business teams as well as through strategic partnerships. Lee, whose background is in molecular biology, considers his move to EngeneOS an “opportunity to do something fun and different.”

— Meredith Salisbury

 

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.